CARE Act of 2025
Summary
The CARE Act of 2025 (S.3145) requires CMS to test a Medicare payment model for ground ambulance dispatches that do not result in transport, creating a new revenue stream for ambulance providers and ancillary services. While only introduced and referred to committee, the bipartisan sponsorship and House companion bill provide credible legislative momentum. Evolent Health ($EVH) and Labcorp ($LH) are positioned as indirect beneficiaries through care coordination platforms and diagnostic lab services, respectively. The bill has no explicit funding authorization — it mandates a model test, not direct appropriations.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The CARE Act creates a new Medicare payment model for non-transport ambulance dispatches, but is early-stage with a long legislative path ahead.
- 2.No direct funding authorization — the bill mandates CMS develop and test a payment model, which could take 2+ years post-enactment to produce actual revenue.
- 3.$EVH has rallied 62.72% in 30 days and may already price in some legislative optimism; $LH at -1.72% has not yet reacted, offering more asymmetric upside.
- 4.Bipartisan sponsorship (Collins-R + Welch-D) and a House companion bill increase structural passage probability but do not accelerate the timeline.
- 5.The 'under arrangement' provision allows third-party contractors (diagnostic labs, care coordination platforms) to directly participate in the new payment model.
Market Implications
The immediate market impact is minimal — the bill is in early legislative stage with no defined funding or timeline. However, the structural shift toward paying for non-transport emergency response creates a long-term revenue expansion for technology platforms that enable care coordination and remote diagnostics. $EVH at $3.72 (near 52-week low) has already begun to discount this opportunity, while $LH at $262.24 has not. Investors should monitor committee activity: a markup or hearing would be a concrete catalyst for these names. The risk is legislative failure or lengthy delay, which would remove the catalyst without near-term earnings support.
Full Analysis
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
What the bill does
Mandatory CMS Innovation Center model test requiring Medicare payment for ground ambulance dispatch without transport, creating a new billing code and revenue stream for care coordination and alternative response services.
Who must act
Centers for Medicare & Medicaid Services (CMS) Innovation Center, must implement payment model within 2 years of enactment for services furnished by ground ambulance providers or entities under arrangement with such providers.
What happens
Creates a new Medicare Part B payment pathway for non-transport emergency response, enabling ambulance providers and their contracted partners to bill for triage, telehealth, and referral services that previously went uncompensated.
Stock impact
Evolent Health ($EVH) provides value-based care platforms and population health management services that could be contracted by ambulance providers to coordinate alternative response programs. The new payment model directly expands the addressable market for care coordination technology in emergency medical services. EVH's recent 7-day +18.53% and 30-day +62.72% rallies likely reflect broader sector momentum; the CARE Act provides additional structural support for revenue growth in this niche.
What the bill does
Medicare payment for non-transport ambulance services may include diagnostic services furnished under arrangement with the ambulance provider, allowing labs to bill for tests performed at scene or via telemedicine during alternative response.
Who must act
Ground ambulance providers and suppliers, who may contract with diagnostic laboratories to furnish testing services during non-transport emergency responses.
What happens
Expands the settings in which Medicare reimburses diagnostic lab services, potentially increasing utilization of point-of-care and remote lab testing in emergency scenarios where patients are treated on-site rather than transported.
Stock impact
Labcorp ($LH) is a national diagnostic laboratory network capable of providing point-of-care testing services and supporting remote lab interpretation for ambulance-based alternative response programs. The bill creates an incremental revenue opportunity for diagnostic services in a new care setting. LH's recent 7-day -0.6% and 30-day -1.72% decline suggest broader headwinds; this legislation provides a targeted upside catalyst.
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
SUPPORT for Patients and Communities Reauthorization Act of 2025
THE LEWIN GROUP, INC.: $11.3M Department of Health and Human Services Contract
CHOICE for Veterans Act of 2025
ASAP Act
Thyroid Disease CARE Act of 2025
PrEP and PEP are Prevention Act
Access to Breast Cancer Diagnosis Act of 2025
Increasing Access to Lung Cancer Screening Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.